The ACDC Study Assessing Cognitive Deterioration in COVID-19

BACKGROUND OF PROPOSED INVESTIGATION Overview A heterogenous cohort of patients, who have been variably denoted as suffering from "Long COVID" or the Post COVID-19 Syndrome, will have persistent cognitive and affective symptoms. A recent large systematic review found that fatigue and objective cognitive impairment were common and persistent after COVID-19 disease with a prevalence of 24.4% and 20.2% respectively (Badenoch et al., 2022). The severity of physical illness associated with SARS-CoV2 infection does not correlate with the likelihood of these symptoms developing or persisting, raising the questions as to the nature of the processes driving post COVID-19 cognitive symptoms. The effects of COVID-19 disease on the brain and the link to cognitive impairment has been emphasised as an area of priority research (Samkaria and Mandal, 2021). There have been proposed mechanistic explanations from case studies (Yesilkaya et al., 2021) as well as more general commentaries on the neuroimmune correlates of COVID-19 disease, (Yesilkaya and Balcioglu, 2020) but as yet no high-quality evidence exists. It is suggested that COVID-19 disease may lead to pathologically identifiable brain changes. A large study evaluating structural brain imaging of patients before and after SARS-CoV2 infection using United Kingdom (UK) Biobank data found evidence of grey matter volume reduction compared with controls (Douaud et al., 2022). This mainly involved olfactory areas but wider limbic involvement was discussed in the context of memory impairment and reported cognitive change. A much smaller study (Hosp et al., 2021) correlated functional imaging changes, Fluoro-Deoxy-Glucose Positron Emission Tomography (FDG-PET), with cognitive impairment in patients hospitalised with COVID-19 disease. Magnetic Resonance Spectroscopy (MRS) is an imaging technology that represents a non-invasive diagnostic tool for evaluating white matter injury in the brain and can provide valuable information regarding underlying pathogenesis. Most importantly, MRS can identify neurochemical abnormalities even in the absence of corresponding findings on structural MR brain imaging. This is important, in that many patients with persistent cognitive symptoms have normal conventional imaging (Hellgren et al., 2021). MRS has been used in a small preliminary study to outline brain inflammation and damage linked to COVID-19 disease (Rapalino et al., 2021). This work pointed to characteristic white matter inflammatory MRS findings in patients with severe and acute COVID-19 disease. White matter changes have also been described using conventional MR imaging in patients presenting with cognitive impairment in association with COVID-19 disease (Hellgren et al., 2021) but such results were not replicated in patients describing "brain fog" symptoms after hospitalisation for COVID-19 disease (Sklinda et al., 2021). Reviewing the nascent investigation already undertaken, there is a possibility that inflammation and other neural correlates play a role in persistent cognitive symptoms in those who have been infected with SARS-CoV2. This pilot study aims to investigate these links as a necessary and urgent first step in trying to understand how and why a significant number of patients are affected in this way. Local relevance NHS Grampian, along with the other health boards in Scotland, has received funding from the Scottish Government to identify and provide intervention for the mental health needs of patients hospitalised with COVID-19 disease. This follows on from Coronavirus (Covid-19): Mental health needs of hospitalised patients - report (https://www.gov.scot/publications/mental-health-needs-patients-hospitalised-due-covid-19/). This has been identified as an unmet need and a clinical priority. The response has seen the creation of the Mental Health After Covid-19 Hospitalisation Team (MACH). NHS Grampian is amongst a small leading group of other boards in rolling out this service and clinicians are currently contacting eligible patients to offer screening appointments as well as developing mental health interventions. NHS Grampian is also moving forward with resources to help staff affected by COVID-19 disease. NHS Grampian's "We Care" programme is expanding to address the identified needs of staff affected by the pandemic, which will include the better identification, understanding and management of 'Long COVID'. There is therefore a significant overlap in the NHS Grampian corporate response for staff and the wider clinical strategy. This underlines the importance and centrality of addressing the longer-term effects of COVID-19 disease for both staff and patients alike. Embedding research within the scope of the work of the MACH team is very important. There is a lot that remains unknown about the COVID-19 disease and meaningful inquiry about associated long term effects is an important and pressing issue. Patients suffering with the long-term sequelae of COVID-19 disease will have a range of needs. In particular, a pressing concern for them is cognitive change. Within NHS Grampian there have been reports anecdotally from significant numbers of patients who have been seen in the MACH clinics so far. The prevalence of cognitive change, specifically impaired recall, has been estimated at 25% of patients from 12 to 18 months after SARS-CoV2 infection (Becker et al., 2021). In a recent large meta-analysis it was found that 32% of patients reported fatigue and 22% had evidence of cognitive impairment 12 weeks or more after SARS-CoV2 infection (Ceban et al., 2022). Investigators plan to offer neuropsychometric testing to all patients who report persistent cognitive symptoms in order to better understand the particular pattern, or phenotype, encountered by patients. It will be important to consider why it is that some patients report prolonged symptoms in general and prolonged cognitive symptoms specifically. Neuroimaging, and spectroscopy specifically, could start to provide answers to these questions. The proposed project will enable research into a common adverse outcome of COVID-19 disease, which has both national recognition and significant morbidity (Ceban et al., 2022).